Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline story, it believes this is somewhat reflected at current levels, with additional proof points required before Sanofi can be considered an “R&D leader,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi to Acquire Dren Bio’s Myeloid Cell Engager to Boost Immunology Pipeline
- Sanofi to acquire Dren Bio’s DR-0201; deal includes $600M upfront payment
- Trump Trade: Administration explores simplified plans for reciprocal tariffs
- Big pharma fears drug price spikes in US-EU tariff spat, Reuters says
- Sanofi starts annual production of vaccines for 2025-26 flu season